X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Average Rating of “Moderate Buy” by Brokerages

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has earned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $9.3750.

Several research firms have recently weighed in on XFOR. Wall Street Zen raised X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Guggenheim began coverage on X4 Pharmaceuticals in a report on Monday, March 9th. They issued a “buy” rating and a $12.00 price objective for the company. Leerink Partners began coverage on X4 Pharmaceuticals in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price objective for the company. Finally, Weiss Ratings downgraded X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 4th.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several hedge funds have recently modified their holdings of XFOR. Bank of America Corp DE lifted its holdings in shares of X4 Pharmaceuticals by 20.3% during the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after purchasing an additional 22,485 shares during the period. Rhumbline Advisers lifted its holdings in shares of X4 Pharmaceuticals by 5.4% during the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after purchasing an additional 9,690 shares during the period. Jane Street Group LLC lifted its holdings in shares of X4 Pharmaceuticals by 112.5% during the second quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after purchasing an additional 51,544 shares during the period. Vanguard Group Inc. lifted its holdings in shares of X4 Pharmaceuticals by 77.0% during the third quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after purchasing an additional 178,593 shares during the period. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of X4 Pharmaceuticals during the third quarter worth $326,000. 72.03% of the stock is owned by institutional investors and hedge funds.

X4 Pharmaceuticals Price Performance

XFOR stock opened at $3.85 on Friday. The company has a market capitalization of $363.13 million, a P/E ratio of -0.85 and a beta of 0.34. X4 Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.83. The business has a 50 day simple moving average of $4.10 and a 200-day simple moving average of $3.88. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.04. The business had revenue of $2.71 million during the quarter, compared to the consensus estimate of $3.20 million. X4 Pharmaceuticals had a negative return on equity of 94.90% and a negative net margin of 1,106.30%. As a group, equities analysts anticipate that X4 Pharmaceuticals will post -0.77 EPS for the current year.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.